侯健多发性骨髓瘤的转化医学研究

. Leukemia 15: 1950, 2001РMitsiades et al. Blood 99: 4525, 2002?Lentzsch et al Cancer Res 62: 2300, 2002 ?LeBlanc R et al. Blood 103: 1787, 2004?Hayashi T et al. Brit J Hematol 128: 192, 2005РPKCРNFATРPI3KРIL-2РCD28Р新发现的免疫调节剂作用机制РKronke et al, Science, 2014 Lu et al, Science,2014РStewart AK, Richardson PG, San Miguel JF Blood 2009Р联合用药方案应用于骨髓瘤一线治疗Р20SР20SР19SР19SРaРbР5, 5i?1, 1i?2, 2iРATPases/?Cdc48РPotential?Therapeutic TargetsР26S PROTEASOMEРATPРADPРUB enzymes E1, E2 and?E3-UB-LigasesРUbРUbРUbРPoly-ubiquitinated proteins? (proteasome substrates)РFreeРfor re-cyclingРSix Protease?activitiesРDegraded proteinРUbРImmunoproteasomeР针对蛋白酶体的新药РDeubiquitylating?Enzymes (DUBs)РBortezomib, ?Carfilzomib, ?CEP-18770?ONYX-0912?MLN 2238РNPI-0052: 5, 1, 2Р5РPR-924РTargeting USP-7?USP14/UCHL 15